p53 and Ovarian Cancer Treatment
Author Information
Author(s): Ferrandina G, Fagotti A, Salerno M G, Natali P G, Mottolese M, Maneschi F, Pasqua A De, Benedetti-Panici P, Mancuso S, Scambia G
Primary Institution: Department of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy
Hypothesis
The study aims to assess the association of p53 status with primary cytoreduction, response to chemotherapy, and outcome in stage III–IV primary ovarian cancer patients.
Conclusion
The study found that p53 positivity is associated with a poorer response to chemotherapy and the ability to perform primary cytoreduction in ovarian cancer patients.
Supporting Evidence
- p53 nuclear positivity was found in 52% of malignant tumours.
- Higher p53 positivity was observed in advanced stage disease compared to early stage.
- p53 positivity was associated with a poor chance of cytoreduction.
- 86% of patients who did not respond to chemotherapy were p53-positive.
Takeaway
This study looked at how a protein called p53 affects treatment for women with advanced ovarian cancer, finding that those with more p53 were less likely to respond well to treatment.
Methodology
Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas.
Participant Demographics
Patients with stage III–IV primary ovarian cancer.
Statistical Information
P-Value
P = 0.0022, P = 0.0038, P = 0.012
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website